According to Zacks, “Teligent, Inc. is a specialty generic pharmaceutical company, develops, manufactures and markets topical formulations primarily in the United States. It sells generic pharmaceutical products in topical, injectable, complex and ophthalmic dosage forms. Teligent Inc., formerly known as IGI Laboratories, Inc., is based in Buena, New Jersey. “
Separately, ValuEngine downgraded Teligent from a “buy” rating to a “hold” rating in a report on Thursday, May 23rd.
Teligent (NASDAQ:TLGT) last released its earnings results on Monday, August 5th. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Teligent had a negative return on equity of 102.17% and a negative net margin of 46.67%. The firm had revenue of $18.34 million for the quarter, compared to the consensus estimate of $17.58 million. As a group, analysts expect that Teligent will post -0.18 earnings per share for the current year.
Several hedge funds and other institutional investors have recently made changes to their positions in TLGT. Sanders Morris Harris LLC lifted its holdings in shares of Teligent by 81.7% in the 2nd quarter. Sanders Morris Harris LLC now owns 3,814,012 shares of the company’s stock worth $2,404,000 after purchasing an additional 1,715,239 shares during the last quarter. First Light Asset Management LLC lifted its holdings in shares of Teligent by 113.3% in the 2nd quarter. First Light Asset Management LLC now owns 3,227,003 shares of the company’s stock worth $2,033,000 after purchasing an additional 1,713,824 shares during the last quarter. Paloma Partners Management Co bought a new stake in shares of Teligent in the 2nd quarter worth approximately $120,000. State of New Jersey Common Pension Fund D bought a new stake in shares of Teligent in the 2nd quarter worth approximately $101,000. Finally, SG Americas Securities LLC bought a new stake in shares of Teligent in the 2nd quarter worth approximately $47,000. 56.07% of the stock is currently owned by institutional investors and hedge funds.
Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. It offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms.
Further Reading: Leveraged Buyout (LBO) Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.